Allena Pharmaceuticals (NASDAQ:ALNAQ – Get Rating) and Humacyte (NASDAQ:HUMA – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Earnings and Valuation

This table compares Allena Pharmaceuticals and Humacyte's revenue, earnings per share and valuation.

Get Allena Pharmaceuticals alerts:

Humacyte has higher revenue and earnings than Allena Pharmaceuticals.

Institutional & Insider Ownership

7.3% of Allena Pharmaceuticals shares are owned by institutional investors. Comparatively, 13.1% of Humacyte shares are owned by institutional investors. 3.7% of Allena Pharmaceuticals shares are owned by company insiders. Comparatively, 25.0% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Allena Pharmaceuticals and Humacyte, as reported by MarketBeat.com.

Humacyte has a consensus target price of $5.88, indicating a potential upside of 112.86%. Given Humacyte's higher probable upside, analysts clearly believe Humacyte is more favorable than Allena Pharmaceuticals.

Risk and Volatility

Allena Pharmaceuticals has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500. Comparatively, Humacyte has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Profitability

This table compares Allena Pharmaceuticals and Humacyte's net margins, return on equity and return on assets.

Summary

Humacyte beats Allena Pharmaceuticals on 9 of the 10 factors compared between the two stocks.

About Allena Pharmaceuticals

(Get Rating)

Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

About Humacyte

(Get Rating)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.